Celularity Names New CFO After David Beers Departs

Celularity Inc reported that David Beers stepped down as chief financial officer, effective June 3, 2026, according to the Form 8-K filed with the SEC that same day.

The filing, submitted under Items 5.02, 7.01 and 9.01, identifies the named individual, the role affected, the effective date and the fact of departure. It does not cite a cause. Item 5.02 requires companies to disclose any departure of a principal officer and to name the successor when one is appointed immediately.

The operational change is direct: Beers no longer serves as CFO. A new chief financial officer has assumed the position as of the same effective date. The filing supplies the successor’s name, biographical details and compensation arrangements in the exhibits required under Item 9.01.

Downstream, the transition starts the clock on multiple regulatory obligations. Celularity must incorporate the updated officer information into its next quarterly report or proxy statement. Any severance, bonus or equity acceleration payable to Beers must be quantified in a subsequent 8-K or 10-Q within the deadlines set by SEC rules.

The new CFO immediately assumes sign-off responsibility for all future Exchange Act filings that require officer certification. Standard stock-exchange notification requirements are also activated.

This marks the latest executive transition at the clinical-stage cell-therapy company, which has operated under Nasdaq compliance pressures and repeated shifts in senior finance leadership in recent years. The 8-K itself constitutes the primary public record; no separate press release was incorporated by reference.

The company listed the full text of the departure announcement and the employment letter of the incoming CFO as exhibits. Those documents will govern any contractual payments or post-employment restrictions that follow from the change.